Maryland State Retirement & Pension System Boosts Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Maryland State Retirement & Pension System grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,607 shares of the biotechnology company’s stock after purchasing an additional 897 shares during the period. Maryland State Retirement & Pension System’s holdings in ADMA Biologics were worth $1,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after purchasing an additional 80,400 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics in the third quarter valued at approximately $61,858,000. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $19,076,000. EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $480,000. Finally, Citigroup Inc. lifted its holdings in ADMA Biologics by 251.7% in the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 0.8 %

ADMA opened at $19.80 on Friday. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The stock has a market capitalization of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60. The business’s 50 day moving average price is $16.76 and its 200 day moving average price is $18.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.